Study of SB-BCLmR-HSPC (BCL11A Enhancer approach) for treatment of transfusion-dependent beta-thalassemia major

Trial Profile

Study of SB-BCLmR-HSPC (BCL11A Enhancer approach) for treatment of transfusion-dependent beta-thalassemia major

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs SB-BCLmR-HSPC (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
    • 13 May 2015 According to a Sangamo BioSciences media release, the decision to change to a BCL11A Enhancer approach will delay the initiation of this trial and it is now expected to begin in 2016.
    • 13 May 2015 Status changed from not yet recruiting to planning, according a Sangamo BioSciences announcing that a new IND application will be submitted for a BCL11A Enhancer approach.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top